Concepedia

SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer

J. Randolph Hecht, Allen Lee Cohn, Shaker R. Dakhil, Mansoor N. Saleh, Bilal Piperdi, Mika Cline-Burkhardt, Ying Tian, William Y. Go

Clinical Colorectal Cancer · 2015 · 115 citations · 25 references

DOI

Concepts

References

25

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 11K citations · Full text

, , +15

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine · 2004 · 5K citations · Full text

, , +17

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text

, , +17

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

Aimery de Gramont, Arié Figer, Michel Seymour et al. · Journal of Clinical Oncology · 2000 · 3.8K citations

, , +11

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Rafael G. Amado, Michael Wolf, Marc Peeters et al. · Journal of Clinical Oncology · 2008 · 3.2K citations · Full text

, , +17